XCancer

[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer

Description:

Fifty (n=50) patients with newly diagnosed ovarian cancer will undergo FAPI PET/CTs in addition to routine diagnostic workup (including FDG PET/CT) at primary staging and restaging. The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT) using histopathology as reference standard, and the diagnostic accuracy will be determined. FAP-immunohistochemistry will be conducted in surgical specimens. FAPI PET/CT's impact on patient management and the prognostic value of FAPI PET/CT will be evaluated.

Sponsor:

Aalborg University Hospital

Phase:

Phase 2

Contacts:

Morten Bentestuen, MD (CONTACT)

m.bentestuen@rn.dk

+4597665500

Government Study Link:

NCT05903807 - Click here to see study on

ClinicalTrials.gov

FAPI-46

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA
Inclusion
  • Can read and understand Danish
  • * Newly diagnosed with biopsy verified ovarian cancer or highly suspected to have ovarian cancer (based on all data presented at the gynecological cancer MDT) and referred to primary staging with FDG PET/CT
  • Considered physically and mentally able to participate in the research project
  • 18-years or older and able to consent to project participation
  • Deemed resectable and operable at the MDT with or without neoadjuvant chemotherapy
Exclusion
  • Subject weighing more than 180 kg (weight limit scanner) or unable to fit within the imaging gantry
  • Patients not suited for surgery or neoadjuvant chemotherapy followed by surgery
  • Patients with an imminent need for surgery or in an emergency
  • * Patients with non-resectable, inoperable, or recurrent ovarian cancer
  • Known concurrent other malignancy within the previous 5 years other than non-melanoma skin cancer